eligibility_summary
Eligibility: MM (IMWG) after ≥2 prior classes (IMiD, PI, anti‑CD38), measurable disease, ECOG 0–1, survival >12 wks, AEs resolved ≤G1, adequate organ/hematologic function, contraception/neg pregnancy test. Exclude: other plasma cell disorders, recent chemo/RT/investigational therapy or transplant, any prior BCMA or BCMA CAR‑T, active GVHD, CNS disease, major cardiac disease/QTc, mAb allergy, steroids/immunosuppression, HBV/HCV/HIV, infection/effusions, recent surgery, pregnancy/lactation, live vaccines, poor compliance/illness.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: YKST02, an intravenous BCMA×CD3 bispecific antibody (T‑cell–engaging biologic). Mechanism of action: binds BCMA (TNFRSF17) on multiple myeloma plasma cells and CD3 on T cells, creating an immune synapse that activates TCR/CD3 signaling and redirects T cells to lyse BCMA-positive tumor cells via perforin/granzyme release and cytokine-driven cytotoxicity. Targets: malignant plasma cells expressing BCMA, effector CD3+ T lymphocytes. Key pathways: BCMA signaling on plasma cells and TCR/CD3 activation in T cells. Trial: first-in-human, Phase 1, open-label, dose escalation/expansion in relapsed/refractory multiple myeloma, IV dosing in 21-day cycles, prior BCMA therapy excluded.